Company Profile
HeartBeam Stock Price, News & Catalysts
- Ticker:
- BEAT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.42 USD (+14.29%)
Close
Last updated: October 1, 2026
48.6M USD
Market cap
Why the stock is moving
The latest monitored company update is “HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.” The corresponding closing-price reaction is not yet available.
Company overview
Ambulatory Cardiac Diagnostics
HeartBeam develops portable electrocardiogram technology intended to detect and monitor cardiac conditions outside traditional clinical settings.
Cardiac Electrical Biomarker Platform
The company reconstructs three-dimensional cardiac electrical information from a compact consumer-oriented device and analyzes it with software and artificial intelligence.
Commercial Care Model
HeartBeam is introducing its system through concierge medical practices and other flagship sites while integrating patient onboarding and clinical workflows.
AI-Enabled Detection
A collaboration with Mount Sinai supports development of next-generation ECG algorithms, beginning with detection of heart attacks.
Future catalysts
- Presentation of heart-attack-detection pilot data at TCT 2026 in fall 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of HeartBeam (BEAT)?
HeartBeam (BEAT) most recently closed at 0.42 USD, a +14.29% move versus the previous session.
What is the market cap of HeartBeam (BEAT)?
HeartBeam currently has a market capitalization of 48.6M USD on BioPharmSignal.
What does HeartBeam do?
Ambulatory Cardiac Diagnostics HeartBeam develops portable electrocardiogram technology intended to detect and monitor cardiac conditions outside traditional clinical settings. Cardiac Electrical Biomarker Platform The company reconstructs three-dimensional cardiac electrical information from a compact consumer-oriented device and analyzes it with software...
On which exchange is BEAT stock listed?
HeartBeam (BEAT) is associated with NASDAQ, United States, Biopharma.
What is Ambulatory?
Ambulatory Cardiac Diagnostics HeartBeam develops portable electrocardiogram technology intended to detect and monitor cardiac conditions outside traditional clinical settings.
Which conditions is HeartBeam targeting with Ambulatory?
Ambulatory Cardiac Diagnostics HeartBeam develops portable electrocardiogram technology intended to detect and monitor cardiac conditions outside traditional clinical settings. Cardiac Electrical Biomarker Platform The company reconstructs three-dimensional cardiac electrical information from a compact consumer-oriented device and analyzes it with software...
How does HeartBeam describe recent progress with Ambulatory?
Presentation of heart-attack-detection pilot data at TCT 2026 in fall 2026.
What is Cardiac?
Ambulatory Cardiac Diagnostics HeartBeam develops portable electrocardiogram technology intended to detect and monitor cardiac conditions outside traditional clinical settings.